New York, NY -- September 27, 2022 -- InvestorsHub NewsWire -- via Stock Market Press -- Stock Market Press is a leading financial news company that delivers up to date stock news. In today’s release, we discuss Endexx Corp (OTC PINK: EDXC), Northwest Biotherapeutics Inc (OTCQB: NWBO), Anavex Life Sciences Corp (NASDAQ: AVXL) and Enzolytics Inc (OTC PINK: ENZC).

The vape industry is growing rapidly. Safety, variety, non-nicotine options and more are driving the market forward. Grand View Research indicated the 2021 market size was $18 billion with a projected compounded annual growth rate of 30% through 2030. Endexx Corp (OTC PINK: EDXC) just completed the acquisition of HYLA, a plant based, non-nicotine vape manufacturer.

Endexx’s HYLA Division Secures Two Purchase Orders Exceeding 200,000 Units

CAVE CREEK, AZ, Sept. 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Endexx Corporation (OTC:EDXC), a provider of innovative, plant-based, and sustainable health and skincare products, today announces that its recently acquired (controlling-interest) HYLA division, secured two major purchase orders for its new innovative vape-delivery product that holds 4500 puffs per built in cartridge unit.

Combined, the orders represent a 150,000-unit order and a 52,000-unit order for over 200,000 units within the first month of the acquisition of Hyla. The newly innovated “No-Nic” (zero- nicotine) vape product produced by HYLA offers 4500 puffs per disposable unit. This expanded puff capacity far exceeds the capacity of its competitor’s products worldwide. Formulated with Guarana and Levodopa, this product is forecasted to replace the recently banned nicotine products sold internationally where vape products are available.

Todd Davis, CEO of Endexx, stated “HYLA’s new product line fills a major gap created by the banning of flavored nicotine vape products. We believe plant-derived products are the alternative and the solution that meets market demands today. The two purchase orders came from prominent distributors in the West Coast region of the US and a large western region in Asia. These orders expand both our international and domestic distribution networks helping to expedite our growth initiatives.”

About Hyla

Hyla develops and distributes zero-nicotine plant-powered, vape-delivered products made with vegan formulations and functional plant extract ingredients. Hyla harnesses the power of Guarana and Levodopa to create plant-derived high-performance botanical products. For more information:  www.tryHyla.com

About Endexx Corporation

Endexx Corporation develops and distributes all natural, plant-derived topical skincare products.  Its products vary from balms, creams, lotions, butters, masks, scrubs, and oils, all with the shared purpose of healthy skin and grooming wellness.  The science behind these products involves a decade of clinical research in the field and lab work to provide functional formulation with ingredients for optimal absorption and support of skin health. www.endexx.com

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

We caution that any forward-looking statements (as such term is defined in the U.S. Private Securities Litigation Reform Act of 1995) contained in this press release or made by us, our management, or our spokespeople involve risks and uncertainties and are subject to change based on various factors, many of which are beyond our control. Accordingly, our future performance and financial results may differ materially from those expressed or implied in any such forward-looking statements. Forward-looking statements include, without limitation, statements regarding our future operating results, the implementation and impact of our strategic plans, and our ability to meet environmental, social, and governance goals. Words such as “estimate,” “commit,” “target,” “goal,” “project,” “plan,” “believe,” “seek,” “strive,” “expect,” “anticipate,” “intend,” “potential” and any similar expressions may identify forward-looking statements. Risks associated with the following factors, among others, could affect our financial performance and cause actual results to differ materially from those expressed or implied in any forward-looking statements:

Except as may be required by law, we assume no obligation and do not intend to make publicly available any update or other revisions to any of the forward-looking statements contained in this press release to reflect circumstances existing after the date of this press release or to reflect the occurrence of future events, even if experience or future events make it clear that any expected results expressed or implied by those forward-looking statements will not be realized. More information on potential factors that could affect our results is included “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2022.

For further information, please contact:

Endexx Corporation
Endexx@endexx.com
480-595-6900

Investors:
Scott Arnold
CORE IR
scotta@coreir.com

Media:
Jules Abraham
CORE IR
julesa@coreir.com
917-885-7378

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the Company's Pediatric Investigation Plan (PIP).  The development, regulatory review and regulatory approval of a PIP is a pre-requisite for application for approval of a new medicine for adult patients, such as DCVax®-L.

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,446,275 to Anavex, with claims to treatment methods using its leading drug candidate, ANAVEX®2-73 (blarcamesine) and its analogs, for ameliorating biochemical and functional abnormalities associated with methyl-CpG binding protein 2 defects (MeCP2 defects).
Such defects encompass a range of neurodevelopmental and neurological disorders, including but not limited to, Rett syndrome, Angelman syndrome, Williams syndrome, cerebral palsy, autism spectrum disorder, and multiple sclerosis.

Enzolytics Inc (OTC PINK: ENZC) looks to have found a bottom over the past few days. One to watch for a rebound back to the $0.055-$0.06 range with any catalysts. Chart: https://www.stockscores.com/chart.asp?TickerSymbol=ENZC&TimeRange=180&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=BB&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=200&Indicator1=RSI&Indicator2=MACD&Indicator3=FStoch&Indicator4=SStoch&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen

Join Stock Market Press' newsletter for the latest in IPO, market commentary and company profiles.
Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.

Contact:
Stock Market Press
110 Wall St.
New York, NY 10005
info@stockmarketpress.com
https://twitter.com/PressStock

Safe Harbor Statement:
Statements in this news release may be ''forward-looking statements.'' Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.

See Stock Market Press disclaimer: http://stockmarketpress.com/disclaimer/

SOURCE: Stock Market Press

Endexx (PK) (USOTC:EDXC)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Endexx (PK) Charts.
Endexx (PK) (USOTC:EDXC)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Endexx (PK) Charts.